Indimitecan (Synonyms: LMP776) |
| Catalog No.GC65939 |
Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 915360-05-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities[1].
Indimitecan (LMP776) (0-100 μM) shows antiproliferative potencies against various human cancer cell lines, with mean-graph midpoint (MGM) of 0.079 ± 0.023 μM[1].
Indimitecan shows potent DNA cleavage due to Top1 inhibition[1].
Indimitecan can be substrates for metabolic ketone reductases[1].
Cell Proliferation Assay[1]
| Cell Line: | HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145, MCF-7 |
| Concentration: | 0-100 μM |
| Incubation Time: | |
| Result: | Showed growth inhibition with GI50s of <0.01, <0.01, 0.04, <0.01, 0.08, <0.01, <0.01 and 0.01 μM against HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145 and MCF-7 cells, respectively. And the mean-graph midpoint (MGM) for growth inhibition of all human cancer cell lines successfully tested (the National Cancer Institute's developmental therapeutics assay (the "NCI60")) was 0.079 ± 0.023 μM. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *